139 related articles for article (PubMed ID: 24042008)
1. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues.
Hong YR; Kim HT; Lee SC; Ro S; Cho JM; Kim IS; Jung YH
Bioorg Med Chem Lett; 2013 Nov; 23(21):5953-7. PubMed ID: 24042008
[TBL] [Abstract][Full Text] [Related]
2. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
[TBL] [Abstract][Full Text] [Related]
4. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation.
Hong YR; Kim HT; Ro S; Cho JM; Lee SH; Kim IS; Jung YH
Bioorg Med Chem Lett; 2014 Jul; 24(14):3142-5. PubMed ID: 24894560
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
7. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
[TBL] [Abstract][Full Text] [Related]
8. Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor.
Arsenault PR; Song D; Bergkamp M; Ravaschiere AM; Navalsky BE; Lieberman PM; Lee FS
Chembiochem; 2016 Dec; 17(24):2316-2323. PubMed ID: 27770548
[TBL] [Abstract][Full Text] [Related]
9. Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.
Deng G; Zhao B; Ma Y; Xu Q; Wang H; Yang L; Zhang Q; Guo TB; Zhang W; Jiao Y; Cai X; Zhang J; Liu H; Guan X; Lu H; Xiang J; Elliott JD; Lin X; Ren F
Bioorg Med Chem; 2013 Nov; 21(21):6349-58. PubMed ID: 24055079
[TBL] [Abstract][Full Text] [Related]
10. 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.
Ahmed S; Ayscough A; Barker GR; Canning HE; Davenport R; Downham R; Harrison D; Jenkins K; Kinsella N; Livermore DG; Wright S; Ivetac AD; Skene R; Wilkens SJ; Webster NA; Hendrick AG
J Med Chem; 2017 Jul; 60(13):5663-5672. PubMed ID: 28594552
[TBL] [Abstract][Full Text] [Related]
11. Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
Li Z; Su K; Jiang Z; Yu Y; You Q; Zhang X
J Med Chem; 2019 Aug; 62(16):7583-7588. PubMed ID: 31244107
[TBL] [Abstract][Full Text] [Related]
12. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
Zhi S; Cai J; Wang H; Tan C; Yang Z; Dai L; Zhang T; Wang H; Li D
Bioorg Med Chem Lett; 2022 Nov; 76():129007. PubMed ID: 36174835
[TBL] [Abstract][Full Text] [Related]
14. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
[TBL] [Abstract][Full Text] [Related]
16. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
[TBL] [Abstract][Full Text] [Related]
17. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
18. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
[TBL] [Abstract][Full Text] [Related]
19. Pyrithione Zn selectively inhibits hypoxia-inducible factor prolyl hydroxylase PHD3.
Na YR; Woo DJ; Kim SY; Yang EG
Biochem Biophys Res Commun; 2016 Apr; 472(2):313-8. PubMed ID: 26940742
[TBL] [Abstract][Full Text] [Related]
20. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
Flamme I; Ellinghaus P; Urrego D; Krüger T
PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
